Azilect

Azilect is a brand name of rasagiline, approved by the FDA in the following formulation(s):

AZILECT (rasagiline mesylate - tablet; oral)

• 
  Manufacturer: TEVA
  
  Approval date: May 16, 2006
  
  Strength(s): EQ 0.5MG BASE, EQ 1MG BASE ^[RLD]

Has a generic version of Azilect been approved?

No. There is currently no therapeutically equivalent version of Azilect available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azilect. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
  Patent 5,387,612
  Issued: February 7, 1995
  Inventor(s): Youdim; Mussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
  Assignee(s): Teva Pharmaceutical Industries Ltd.
  Technion Research and Development Foundation Ltd.
  R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
  
  Patent expiration dates:
  
  
  • February 7, 2012
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
  
  



• 
  Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
  Patent 5,453,446
  Issued: September 26, 1995
  Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
  Assignee(s): Teva Pharmaceutical Industries, Ltd.
  Technion Research and Development Foundation Ltd.
  R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
  
  Patent expiration dates:
  
  
  • February 7, 2017
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
  
  



• 
  R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them
  Patent 5,457,133
  Issued: October 10, 1995
  Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim
  Assignee(s): Teva Pharmaceutical Industries Ltd.
  Technion Research and Development Foundation Ltd.
  R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
  
  Patent expiration dates:
  
  
  • February 7, 2012
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
  Patent 5,532,415
  Issued: July 2, 1996
  Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim & Veinberg; Alex
  Assignee(s): Teva Pharmaceutical Industries Ltd.
  Technion Research and Development Foundation Ltd.
  The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
  
  Patent expiration dates:
  
  
  • July 2, 2013
    
    ✓ 
    Drug substance
  
  



• 
  Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
  Patent 5,786,390
  Issued: July 28, 1998
  Inventor(s): Youdim; Moussa B. H. & Finberg; John P. M. & Levy; Ruth & Sterling; Jeffrey & Lerner; David & Berger-Paskin; Tirtsah & Yellin; Haim & Veinberg; Alex
  Assignee(s): Teva Pharmaceutical Industries Ltd.
  Technion Research and Development Foundation Ltd.
  The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.
  
  Patent expiration dates:
  
  
  • February 7, 2012
    
    ✓ 
    Drug product
  
  



• 
  Stable compositions containing N-propargyl-1-aminoindan
  Patent 6,126,968
  Issued: October 3, 2000
  Inventor(s): Peskin; Tirtsah Berger & Caciularu; Fanny
  Assignee(s): Teva Pharmaceutical Industries, Ltd.
  A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one pentahydric or hexahydric alcohol. Optionally the composition may contain citric acid and magnesium stearate.
  
  Patent expiration dates:
  
  
  • September 18, 2016
    
    ✓ 
    Drug product
  
  



• 
  Rasagiline formulations and processes for their preparation
  Patent 7,572,834
  Issued: August 11, 2009
  Inventor(s): Sterling; Jeffrey & Lerner; David & Rosen; Harel & Bronov; Leonid & Medini-Green; Dalia & Iosefzon; Berta & Berger-Peskin; Tirtsah & Lidor-Hadas; Ramy & Bahar; Eliezer
  Assignee(s): Teva Pharmaceutical Industries, Ltd.
  The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.
  
  Patent expiration dates:
  
  
  • December 5, 2026
    
    ✓ 
    Drug product
  
  



• 
  Rasagiline formulations of improved content uniformity
  Patent 7,815,942
  Issued: October 19, 2010
  Inventor(s): Peskin; Tirtza Berger
  Assignee(s): Teva Pharmaceutical Industries, Ltd.
  Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.
  
  Patent expiration dates:
  
  
  • August 27, 2027
    
    ✓ 
    Patent use: TREATMENT OF PARKINSON'S DISEASE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 16, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Azilect Consumer Information (Drugs.com)
• Azilect Consumer Information (Wolters Kluwer)
• Azilect Consumer Information (Cerner Multum)
• Azilect Advanced Consumer Information (Micromedex)
• Azilect AHFS DI Monographs (ASHP)
• Rasagiline Consumer Information (Wolters Kluwer)
• Rasagiline Consumer Information (Cerner Multum)
• Rasagiline Advanced Consumer Information (Micromedex)
• Rasagiline Mesylate AHFS DI Monographs (ASHP)